Cue Biopharma, Inc.
CUE
$30.44
$1.364.68%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 921.03% | -27.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 921.03% | -27.25% | |||
| Cost of Revenue | 283.53% | -47.48% | |||
| Gross Profit | 399.75% | 59.54% | |||
| SG&A Expenses | -26.85% | 50.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 106.17% | -16.36% | |||
| Operating Income | 125.95% | 12.63% | |||
| Income Before Tax | 127.99% | 12.19% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 121.28% | 12.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 121.28% | 12.19% | |||
| EBIT | 125.95% | 12.63% | |||
| EBITDA | 135.32% | 12.56% | |||
| EPS Basic | 119.88% | 16.90% | |||
| Normalized Basic EPS | 126.07% | 17.47% | |||
| EPS Diluted | 119.43% | 16.90% | |||
| Normalized Diluted EPS | 125.48% | 17.47% | |||
| Average Basic Shares Outstanding | 7.06% | 5.67% | |||
| Average Diluted Shares Outstanding | 9.56% | 5.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||